Abivax announces the start of the roadshow for its proposed global offering and proposed nasdaq listing

Paris, france / accesswire / october 16, 2023 / abivax sa (euronext paris: fr0012333284 - abvx) ("abivax" or the "company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the start of its roadshow in connection with its intention to issue, subject to market and other conditions, 18,675,500 ordinary shares of the company in an initial public offering of american depositary shares ("adss"), each representing one ordinary share, in the united states (the "u.s. offering") and a concurrent offering of ordinary shares in certain jurisdictions outside of the united states (the "european private placement", and together, the "global offering"). abivax intends to grant the underwriters a 30-day option to purchase additional adss and/or ordinary shares in an aggregate amount of up to 15% of the total number of adss and ordinary shares proposed to be sold in the global offering.
ABVX Ratings Summary
ABVX Quant Ranking